RxDoctor Payments Data

Isabelle Vonalthen-Dagum, MD

Gastroenterology · East Setauket, NYNPI 1598789760

Payments from drug & device makers

$4,300in general payments, 2019–2025

Across 141 payments — averaging $30.50 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • Johnson & Johnson$425
  • Nestle Healthcare Nutrition Inc.$371
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$317
  • E.r. Squibb & Sons, L.L.C.$239
  • Ferring Pharmaceuticals Inc.$198
  • plus $1K from 19 others

What the payments were for

  • Food & beverage$4,284100%
  • Education$160%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,300 in reported general payments places this provider in the 60th percentile of 1,682 gastroenterology providers in New York.

See all gastroenterology providers in New York

Medicare billing

Part B allowed, 2024
$118,594
Medicare patients
337
Services billed
751

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Humira PenAdalimumab13$179,284
CreonLipase/Protease/Amylase14$41,927
LinzessLinaclotide29$35,118
VoqueznaVonoprazan Fumarate15$16,054
Mesalamine11$9,699
CholestyramineCholestyramine (With Sugar)12$1,550
Omeprazole125$1,176
Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates14$707
Pantoprazole Sodium40$562
Rabeprazole Sodium15$459
Gavilyte-GPeg3350/Sod Sulf,bicarb,cl/Kcl23$347
Sucralfate22$344
Famotidine29$232
Lactulose14$93

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieCreon, Linzess$1,361$77,04543 claims
Phathom Pharmaceuticals, Inc.Voquezna$125$16,05415 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 1,682 gastroenterology providers in New York.

Other gastroenterology in East Setauket

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →